Who are BRII-296's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tozinameran 6 months to 4 years of age, TT, Influenza, Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), Comirnaty Original/Omicron BA.4-5, Tozinameran 12 Years of age and older.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brii-296.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

BRII-296 — Competitive Intelligence Brief

BRII-296 (BRII-296) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Infectious disease.

phase 2 Monoclonal antibody SARS-CoV-2 spike protein Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

BRII-296 (BRII-296) — Brii Biosciences Limited. BRII-296 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BRII-296 TARGET	BRII-296	Brii Biosciences Limited	phase 2	Monoclonal antibody	SARS-CoV-2 spike protein
Tozinameran 6 months to 4 years of age	tozinameran-6-months-to-4-years-of-age	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
TT	TT	CanSino Biologics Inc.	marketed	Viral vector vaccine	SARS-CoV-2 spike protein
Influenza	Influenza and COVID-19 Combination A	BioNTech	marketed	Non-Standardized Plant Allergenic Extract [EPC]	SARS-CoV-2 spike protein and influenza hemagglutinin protein
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Comirnaty Original/Omicron BA.4-5	Comirnaty Original/Omicron BA.4-5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants)
Tozinameran 12 Years of age and older	tozinameran-12-years-of-age-and-older	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BRII-296 — Competitive Intelligence Brief. https://druglandscape.com/ci/brii-296. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab